Bright Minds Biosciences Inc. (NASDAQ: DRUG) Stock Competitors & Peer Comparison
See DRUG's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DRUG and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DRUG | $77.42 | -1.45% | 757.7M | -37.22 | -$2.08 | N/A |
| VRTX | $548.05 | +1.44% | 139.1B | 28.80 | $19.03 | N/A |
| REGN | $834.04 | +0.90% | 85.9B | 18.28 | $45.63 | +0.44% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,039.78 | +0.16% | 64.7B | 93.84 | $11.08 | N/A |
| MRNA | $145.13 | +8.86% | 57.6B | -17.81 | -$8.15 | N/A |
| RVMDW | $11.80 | -3.83% | 46.3B | -1.64 | -$7.21 | N/A |
| RVMD | $209.46 | -1.07% | 44.5B | -23.75 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $374.47 | +1.44% | 40B | 65.93 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
DRUG vs VRTX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, VRTX has a market cap of 139.1B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while VRTX trades at $548.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas VRTX's P/E ratio is 28.80. In terms of profitability, DRUG's ROE is -0.13%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, DRUG is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
DRUG vs REGN Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, REGN has a market cap of 85.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while REGN trades at $834.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas REGN's P/E ratio is 18.28. In terms of profitability, DRUG's ROE is -0.13%, compared to REGN's ROE of +0.14%. Regarding short-term risk, DRUG is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
DRUG vs VRNA Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas VRNA's P/E ratio is -102.80. In terms of profitability, DRUG's ROE is -0.13%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, DRUG is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
DRUG vs ARGX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ARGX has a market cap of 64.7B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ARGX trades at $1,039.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ARGX's P/E ratio is 93.84. In terms of profitability, DRUG's ROE is -0.13%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, DRUG is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
DRUG vs MRNA Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, MRNA has a market cap of 57.6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while MRNA trades at $145.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas MRNA's P/E ratio is -17.81. In terms of profitability, DRUG's ROE is -0.13%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, DRUG is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
DRUG vs RVMDW Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, RVMDW has a market cap of 46.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while RVMDW trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas RVMDW's P/E ratio is -1.64. In terms of profitability, DRUG's ROE is -0.13%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, DRUG is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
DRUG vs RVMD Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, RVMD has a market cap of 44.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while RVMD trades at $209.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas RVMD's P/E ratio is -23.75. In terms of profitability, DRUG's ROE is -0.13%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, DRUG is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
DRUG vs SGEN Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DRUG's ROE is -0.13%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DRUG is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
DRUG vs ONC Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ONC has a market cap of 40B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ONC trades at $374.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ONC's P/E ratio is 65.93. In terms of profitability, DRUG's ROE is -0.13%, compared to ONC's ROE of +0.14%. Regarding short-term risk, DRUG is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
DRUG vs ALNY Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ALNY has a market cap of 31.6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ALNY trades at $236.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ALNY's P/E ratio is 42.56. In terms of profitability, DRUG's ROE is -0.13%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, DRUG is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
DRUG vs BNTX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, BNTX has a market cap of 29.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while BNTX trades at $116.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas BNTX's P/E ratio is -15.12. In terms of profitability, DRUG's ROE is -0.13%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, DRUG is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
DRUG vs INSM Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, INSM has a market cap of 27.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while INSM trades at $125.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas INSM's P/E ratio is -30.60. In terms of profitability, DRUG's ROE is -0.13%, compared to INSM's ROE of -1.11%. Regarding short-term risk, DRUG is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
DRUG vs ROIV Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ROIV has a market cap of 26.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ROIV trades at $36.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ROIV's P/E ratio is -34.53. In terms of profitability, DRUG's ROE is -0.13%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, DRUG is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
DRUG vs INCY Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, INCY has a market cap of 25.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while INCY trades at $127.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas INCY's P/E ratio is 17.18. In terms of profitability, DRUG's ROE is -0.13%, compared to INCY's ROE of +0.30%. Regarding short-term risk, DRUG is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
DRUG vs UTHR Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, UTHR has a market cap of 21.8B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while UTHR trades at $513.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas UTHR's P/E ratio is 18.36. In terms of profitability, DRUG's ROE is -0.13%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, DRUG is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
DRUG vs GMAB Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, GMAB has a market cap of 20.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while GMAB trades at $33.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas GMAB's P/E ratio is 25.21. In terms of profitability, DRUG's ROE is -0.13%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, DRUG is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
DRUG vs BGNE Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DRUG's ROE is -0.13%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, DRUG is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
DRUG vs DNA-WT Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, DRUG's ROE is -0.13%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, DRUG is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
DRUG vs JAZZ Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while JAZZ trades at $254.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas JAZZ's P/E ratio is 9.48. In terms of profitability, DRUG's ROE is -0.13%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, DRUG is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
DRUG vs BBIO Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, BBIO has a market cap of 16B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while BBIO trades at $81.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas BBIO's P/E ratio is -21.79. In terms of profitability, DRUG's ROE is -0.13%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, DRUG is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
DRUG vs ASND Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ASND trades at $253.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ASND's P/E ratio is -104.67. In terms of profitability, DRUG's ROE is -0.13%, compared to ASND's ROE of +1.90%. Regarding short-term risk, DRUG is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
DRUG vs NBIX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, NBIX has a market cap of 15.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while NBIX trades at $152.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas NBIX's P/E ratio is 22.05. In terms of profitability, DRUG's ROE is -0.13%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, DRUG is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
DRUG vs EXEL Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, EXEL has a market cap of 13.6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while EXEL trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas EXEL's P/E ratio is 15.45. In terms of profitability, DRUG's ROE is -0.13%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, DRUG is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check EXEL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
DRUG vs BMRN Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, BMRN has a market cap of 12.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while BMRN trades at $66.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas BMRN's P/E ratio is 32.07. In terms of profitability, DRUG's ROE is -0.13%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, DRUG is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check BMRN's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
DRUG vs HALO Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, HALO has a market cap of 12.8B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while HALO trades at $108.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas HALO's P/E ratio is 20.18. In terms of profitability, DRUG's ROE is -0.13%, compared to HALO's ROE of +1.81%. Regarding short-term risk, DRUG is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
DRUG vs KRTX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DRUG's ROE is -0.13%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DRUG is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
DRUG vs ARWR Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ARWR has a market cap of 12.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ARWR trades at $87.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ARWR's P/E ratio is -38.72. In terms of profitability, DRUG's ROE is -0.13%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, DRUG is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
DRUG vs MDGL Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while MDGL trades at $516.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas MDGL's P/E ratio is -40.37. In terms of profitability, DRUG's ROE is -0.13%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, DRUG is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
DRUG vs TECH Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while TECH trades at $72.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas TECH's P/E ratio is 37.28. In terms of profitability, DRUG's ROE is -0.13%, compared to TECH's ROE of +0.09%. Regarding short-term risk, DRUG is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
DRUG vs RNAM Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas RNAM's P/E ratio is -17.39. In terms of profitability, DRUG's ROE is -0.13%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, DRUG is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
DRUG vs AXSM Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while AXSM trades at $207.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas AXSM's P/E ratio is -54.25. In terms of profitability, DRUG's ROE is -0.13%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, DRUG is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check AXSM's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
DRUG vs SMMT Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, SMMT has a market cap of 10.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while SMMT trades at $13.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas SMMT's P/E ratio is -11.75. In terms of profitability, DRUG's ROE is -0.13%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, DRUG is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check SMMT's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
DRUG vs PRAX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, PRAX has a market cap of 10.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while PRAX trades at $375.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas PRAX's P/E ratio is -29.08. In terms of profitability, DRUG's ROE is -0.13%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, DRUG is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check PRAX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
DRUG vs KRYS Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while KRYS trades at $346.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas KRYS's P/E ratio is 43.43. In terms of profitability, DRUG's ROE is -0.13%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, DRUG is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check KRYS's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
DRUG vs PTGX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, PTGX has a market cap of 9.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while PTGX trades at $154.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas PTGX's P/E ratio is 149.90. In terms of profitability, DRUG's ROE is -0.13%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, DRUG is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check PTGX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
DRUG vs IONS Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, IONS has a market cap of 9.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while IONS trades at $59.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas IONS's P/E ratio is -34.73. In terms of profitability, DRUG's ROE is -0.13%, compared to IONS's ROE of -1.11%. Regarding short-term risk, DRUG is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check IONS's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
DRUG vs KYMR Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, KYMR has a market cap of 9.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while KYMR trades at $119.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas KYMR's P/E ratio is -37.44. In terms of profitability, DRUG's ROE is -0.13%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, DRUG is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check KYMR's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
DRUG vs CYTK Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while CYTK trades at $76.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas CYTK's P/E ratio is -10.64. In terms of profitability, DRUG's ROE is -0.13%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, DRUG is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
DRUG vs RXDX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DRUG's ROE is -0.13%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DRUG is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check RXDX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
DRUG vs SYRE Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, SYRE has a market cap of 9.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while SYRE trades at $106.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas SYRE's P/E ratio is -54.61. In terms of profitability, DRUG's ROE is -0.13%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, DRUG is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
DRUG vs IMVT Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, IMVT has a market cap of 9.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while IMVT trades at $44.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas IMVT's P/E ratio is -15.73. In terms of profitability, DRUG's ROE is -0.13%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, DRUG is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check IMVT's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
DRUG vs NUVL Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas NUVL's P/E ratio is -21.79. In terms of profitability, DRUG's ROE is -0.13%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, DRUG is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check NUVL's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
DRUG vs PCVX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, PCVX has a market cap of 9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while PCVX trades at $62.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas PCVX's P/E ratio is -8.21. In terms of profitability, DRUG's ROE is -0.13%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, DRUG is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check PCVX's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
DRUG vs CRNX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while CRNX trades at $84.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas CRNX's P/E ratio is -16.80. In terms of profitability, DRUG's ROE is -0.13%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, DRUG is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
DRUG vs IMGN Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DRUG's ROE is -0.13%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, DRUG is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
DRUG vs ABVX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ABVX has a market cap of 8.4B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ABVX trades at $114.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ABVX's P/E ratio is -60.25. In terms of profitability, DRUG's ROE is -0.13%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, DRUG is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
DRUG vs BPMC Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas BPMC's P/E ratio is -51.58. In terms of profitability, DRUG's ROE is -0.13%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, DRUG is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
DRUG vs APGE Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while APGE trades at $134.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas APGE's P/E ratio is -31.12. In terms of profitability, DRUG's ROE is -0.13%, compared to APGE's ROE of -0.30%. Regarding short-term risk, DRUG is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check APGE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
DRUG vs TGTX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while TGTX trades at $54.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas TGTX's P/E ratio is 19.66. In terms of profitability, DRUG's ROE is -0.13%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, DRUG is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
DRUG vs CERE Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas CERE's P/E ratio is -16.47. In terms of profitability, DRUG's ROE is -0.13%, compared to CERE's ROE of -0.72%. Regarding short-term risk, DRUG is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
DRUG vs IBRX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, IBRX has a market cap of 8.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while IBRX trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas IBRX's P/E ratio is -8.03. In terms of profitability, DRUG's ROE is -0.13%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, DRUG is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check IBRX's competition here
Alkermes plc (NASDAQ: ALKS)
DRUG vs ALKS Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ALKS has a market cap of 8.1B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ALKS trades at $48.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ALKS's P/E ratio is 50.87. In terms of profitability, DRUG's ROE is -0.13%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, DRUG is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ALKS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
DRUG vs RYTM Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while RYTM trades at $110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas RYTM's P/E ratio is -35.35. In terms of profitability, DRUG's ROE is -0.13%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, DRUG is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check RYTM's competition here
Metsera, Inc. (NASDAQ: MTSR)
DRUG vs MTSR Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas MTSR's P/E ratio is -23.58. In terms of profitability, DRUG's ROE is -0.13%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, DRUG is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
DRUG vs CAI Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while CAI trades at $26.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas CAI's P/E ratio is 69.06. In terms of profitability, DRUG's ROE is -0.13%, compared to CAI's ROE of +0.19%. Regarding short-term risk, DRUG is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check CAI's competition here
CG Oncology Inc. (NASDAQ: CGON)
DRUG vs CGON Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, CGON has a market cap of 6.8B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while CGON trades at $79.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas CGON's P/E ratio is -28.85. In terms of profitability, DRUG's ROE is -0.13%, compared to CGON's ROE of -0.25%. Regarding short-term risk, DRUG is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
DRUG vs MRUS Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas MRUS's P/E ratio is -17.05. In terms of profitability, DRUG's ROE is -0.13%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, DRUG is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check MRUS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
DRUG vs SRRK Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, SRRK has a market cap of 6.8B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while SRRK trades at $56.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas SRRK's P/E ratio is -16.38. In terms of profitability, DRUG's ROE is -0.13%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, DRUG is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check SRRK's competition here
Arcellx, Inc. (NASDAQ: ACLX)
DRUG vs ACLX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ACLX's P/E ratio is -28.27. In terms of profitability, DRUG's ROE is -0.13%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, DRUG is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
DRUG vs RETA Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas RETA's P/E ratio is -66.29. In terms of profitability, DRUG's ROE is -0.13%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DRUG is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check RETA's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
DRUG vs ORKA Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ORKA has a market cap of 6.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ORKA trades at $107.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ORKA's P/E ratio is -55.65. In terms of profitability, DRUG's ROE is -0.13%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, DRUG is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check ORKA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
DRUG vs BLTE Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while BLTE trades at $161.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas BLTE's P/E ratio is -86.13. In terms of profitability, DRUG's ROE is -0.13%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, DRUG is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
DRUG vs CNTA Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas CNTA's P/E ratio is -22.63. In terms of profitability, DRUG's ROE is -0.13%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, DRUG is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check CNTA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
DRUG vs DNTH Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, DNTH has a market cap of 6.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while DNTH trades at $111.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas DNTH's P/E ratio is -26.77. In terms of profitability, DRUG's ROE is -0.13%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, DRUG is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check DNTH's competition here
Erasca, Inc. (NASDAQ: ERAS)
DRUG vs ERAS Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ERAS has a market cap of 6.1B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ERAS trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ERAS's P/E ratio is -18.96. In terms of profitability, DRUG's ROE is -0.13%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, DRUG is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check ERAS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
DRUG vs TVTX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, TVTX has a market cap of 6.1B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while TVTX trades at $65.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas TVTX's P/E ratio is -146.02. In terms of profitability, DRUG's ROE is -0.13%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, DRUG is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check TVTX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
DRUG vs COGT Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, COGT has a market cap of 6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while COGT trades at $36.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas COGT's P/E ratio is -16.73. In terms of profitability, DRUG's ROE is -0.13%, compared to COGT's ROE of -0.73%. Regarding short-term risk, DRUG is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check COGT's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
DRUG vs DFTX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, DFTX has a market cap of 6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while DFTX trades at $44.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas DFTX's P/E ratio is N/A. In terms of profitability, DRUG's ROE is -0.13%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, DRUG is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check DFTX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
DRUG vs XENE Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, XENE has a market cap of 5.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while XENE trades at $60.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas XENE's P/E ratio is -12.93. In terms of profitability, DRUG's ROE is -0.13%, compared to XENE's ROE of -0.44%. Regarding short-term risk, DRUG is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check XENE's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
DRUG vs MIRM Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while MIRM trades at $96.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas MIRM's P/E ratio is -6.62. In terms of profitability, DRUG's ROE is -0.13%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, DRUG is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check MIRM's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
DRUG vs PTCT Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while PTCT trades at $69.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas PTCT's P/E ratio is -29.97. In terms of profitability, DRUG's ROE is -0.13%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, DRUG is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check PTCT's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
DRUG vs LGND Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while LGND trades at $286.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas LGND's P/E ratio is 31.43. In terms of profitability, DRUG's ROE is -0.13%, compared to LGND's ROE of +0.20%. Regarding short-term risk, DRUG is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
DRUG vs CDTX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas CDTX's P/E ratio is -19.77. In terms of profitability, DRUG's ROE is -0.13%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, DRUG is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check CDTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
DRUG vs CRSP Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while CRSP trades at $59.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas CRSP's P/E ratio is -12.21. In terms of profitability, DRUG's ROE is -0.13%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, DRUG is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check CRSP's competition here
Abcam plc (NASDAQ: ABCM)
DRUG vs ABCM Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DRUG's ROE is -0.13%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DRUG is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
DRUG vs ISEE Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DRUG's ROE is -0.13%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DRUG is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
DRUG vs APLS Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas APLS's P/E ratio is 38.35. In terms of profitability, DRUG's ROE is -0.13%, compared to APLS's ROE of +0.40%. Regarding short-term risk, DRUG is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
DRUG vs ACAD Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ACAD has a market cap of 5.1B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ACAD trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ACAD's P/E ratio is 13.29. In terms of profitability, DRUG's ROE is -0.13%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, DRUG is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
DRUG vs DYN Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while DYN trades at $26.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas DYN's P/E ratio is -8.11. In terms of profitability, DRUG's ROE is -0.13%, compared to DYN's ROE of -0.64%. Regarding short-term risk, DRUG is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check DYN's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
DRUG vs TERN Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas TERN's P/E ratio is -51.41. In terms of profitability, DRUG's ROE is -0.13%, compared to TERN's ROE of -0.20%. Regarding short-term risk, DRUG is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
DRUG vs EWTX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while EWTX trades at $44.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas EWTX's P/E ratio is -23.88. In terms of profitability, DRUG's ROE is -0.13%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, DRUG is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
DRUG vs PBLS Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while PBLS trades at $39.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas PBLS's P/E ratio is -44.73. In terms of profitability, DRUG's ROE is -0.13%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, DRUG is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check PBLS's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
DRUG vs FOLD Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas FOLD's P/E ratio is -161.00. In terms of profitability, DRUG's ROE is -0.13%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, DRUG is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
DRUG vs AKRO Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas AKRO's P/E ratio is -14.57. In terms of profitability, DRUG's ROE is -0.13%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, DRUG is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
DRUG vs ALPN Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DRUG's ROE is -0.13%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, DRUG is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ALPN's competition here
Celcuity Inc. (NASDAQ: CELC)
DRUG vs CELC Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while CELC trades at $93.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas CELC's P/E ratio is -21.06. In terms of profitability, DRUG's ROE is -0.13%, compared to CELC's ROE of -3.51%. Regarding short-term risk, DRUG is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check CELC's competition here
Veradermics, Incorporated (NYSE: MANE)
DRUG vs MANE Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, MANE has a market cap of 4.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while MANE trades at $102.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas MANE's P/E ratio is -32.79. In terms of profitability, DRUG's ROE is -0.13%, compared to MANE's ROE of -0.29%. Regarding short-term risk, DRUG is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check MANE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
DRUG vs AMLX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, AMLX has a market cap of 4.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while AMLX trades at $38.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas AMLX's P/E ratio is -25.77. In terms of profitability, DRUG's ROE is -0.13%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, DRUG is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check AMLX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
DRUG vs ELVN Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ELVN has a market cap of 4.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ELVN trades at $59.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ELVN's P/E ratio is -35.82. In terms of profitability, DRUG's ROE is -0.13%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, DRUG is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check ELVN's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
DRUG vs RLAY Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, RLAY has a market cap of 4.3B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while RLAY trades at $19.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas RLAY's P/E ratio is -12.38. In terms of profitability, DRUG's ROE is -0.13%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, DRUG is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check RLAY's competition here
Opthea Limited (NASDAQ: OPT)
DRUG vs OPT Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas OPT's P/E ratio is -1.52. In terms of profitability, DRUG's ROE is -0.13%, compared to OPT's ROE of +1.18%. Regarding short-term risk, DRUG is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
DRUG vs PRTC Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas PRTC's P/E ratio is -3.78. In terms of profitability, DRUG's ROE is -0.13%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, DRUG is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check PRTC's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
DRUG vs ADPT Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while ADPT trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas ADPT's P/E ratio is -63.39. In terms of profitability, DRUG's ROE is -0.13%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, DRUG is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check ADPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
DRUG vs MRTX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DRUG's ROE is -0.13%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DRUG is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check MRTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
DRUG vs LEGN Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while LEGN trades at $21.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas LEGN's P/E ratio is -32.09. In terms of profitability, DRUG's ROE is -0.13%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, DRUG is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check LEGN's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
DRUG vs DNLI Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, DNLI has a market cap of 4B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while DNLI trades at $24.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas DNLI's P/E ratio is -8.65. In terms of profitability, DRUG's ROE is -0.13%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, DRUG is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check DNLI's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
DRUG vs VKTX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while VKTX trades at $33.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas VKTX's P/E ratio is -7.27. In terms of profitability, DRUG's ROE is -0.13%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, DRUG is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check VKTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
DRUG vs TNGX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while TNGX trades at $23.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas TNGX's P/E ratio is -28.77. In terms of profitability, DRUG's ROE is -0.13%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, DRUG is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for DRUG.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
DRUG vs CPRX Comparison August 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRUG stands at 757.7M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, DRUG is priced at $77.42 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRUG currently has a P/E ratio of -37.22, whereas CPRX's P/E ratio is 12.30. In terms of profitability, DRUG's ROE is -0.13%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, DRUG is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for DRUG.Check CPRX's competition here